Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lexaria Bioscience ( (LEXX) ) is now available.
Lexaria Bioscience is progressing with its Phase 1b human study in Australia, investigating the safety and efficacy of its DehydraTECH-tirzepatide formulation for diabetes control and weight loss. The study has received ethical approval for all initial study arms, and plans are underway to add a fifth arm based on promising prior results that showed improved blood glucose reduction and fewer adverse events when using DehydraTECH technology. This development marks a significant step in Lexaria’s efforts to shift diabetes treatment from injections to oral delivery systems, potentially enhancing patient experience and compliance.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the efficacy and safety of drug formulations. The company is known for its proprietary DehydraTECH technology, which aims to improve the oral delivery of drugs, particularly in the areas of diabetes control and weight management.
YTD Price Performance: -23.04%
Average Trading Volume: 192,036
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $31.07M
See more insights into LEXX stock on TipRanks’ Stock Analysis page.